StockData

Jyong Biotech Ltd. (MENS) stock

MENSNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026Score 0/30
$1.86+0.06 (+3.33%)

Close on Nov 18, 2026Market cap $141.41MP/E –Yield –

Jyong Biotech ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$2.51M.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.51M–
FY2024Dec 31, 2024-$1.94M–
FY2023Dec 31, 2023-$2.67M–

More Jyong Biotech figures

See a number that looks wrong?